Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2019-11-19
2024-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Muscular Changes in the First 12 Weeks After Stroke.
NCT06320561
Strengthening in Sub-acute Stroke Survivors: A Randomized Controlled Trial
NCT06140381
Impact of Muscular Fatigability on Spastic Co-contractions After Stroke Patients
NCT03342820
Muscle Tone Changes in Acute Stroke According to Brain Injury
NCT01041560
Exoskeleton-assisted Training to Accelerate Walking Recovery Early After Stroke: the TARGET Phase II Study
NCT03727919
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Two longitudinal prospective cohort studies will be conducted in which non-ambulatory (cohort 1) and ambulatory (cohort 2) acute stroke patients will participate.
PATIENT RECRUITMENT:
The investigators aim to recruit 200 subjects (100/cohort). Patients will be recruited at the Neurology ward of the UZ Brussel.
PROCEDURE:
All stroke survivors admitted to the Neurology ward of UZ Brussel will be screened for eligibility. Afterwards, an informed consent will be conducted for all subjects who met the inclusion criteria.
Baseline assessments (T0) of gait recovery outcomes on the one hand and predictors for gait recovery on the other hand will be measured. To predict gait recovery, researchers will observe two novel biomarkers: stroke-induced muscle wasting and inflammation. Furthermore, the investigators will also assess relevant known predictors for gait recovery to compare the relevance of the novel markers. T0 assessments will start preferably within 3 days post-stroke.
To assess time-related trajectories of muscle alterations and inflammation, follow-up assessments of these predictors will be performed 3 days after baseline assessments (T1), at discharge (T2) and 3 months follow-up (T3). T1 follow-up measurements will only be possible for patients with motor impairments post-stroke since they have a longer stay at the hospital compared to patients without motor impairments after stroke (mean hospital stay of 5 to 8 days for patients without or with motor impairments post-stroke respectively).
The assessments of the gait recovery outcome measures will be repeated at discharge (T2) and 3 months follow-up (T3).
MATERIALS:
To measure gait recovery in acute stroke survivors, the researchers will make use of wearable gait sensors (Physiolog®, Gait Up SA, Switzerland) to register gait speed and a lightweight chest carrying gas analysis system (Metamax 3B, Cortex, Germany) to measure cardiorespiratory parameters.
For the predictors, investigators will use handheld dynamometers (MicroFET2 and Martin Vigorimeter) to assess muscle strength, grip strength and muscle fatigue. Furthermore, researchers need a Bioelectrical Impedance analysis (BIA) device (Bodystat® QuadScan 4000, UK) to assess the muscle mass of our subjects and a portable ultrasound system (Viamo SV 7 with linear-array transducer, Canon Medical Systems, Netherlands) to assess muscle architecture.
STATISTICAL ANALYSIS:
Various biomarkers will be observed at each of the planned time points. Because the aim is to make correct predictions based on any information that is available at the early stages, the observations will not only be considered as such, but also summarized in terms of their time- related characteristics, such as steepest drop, frequency of improvement, or any other characteristic that may reveal itself as distinguishing. These predictors will be combined into predictive models such as random forests and boosting to establish the best combinations for making good predictions while accommodating inter-predictor correlations. The quality of the models will be established with cross-validation. The large set of observations and their summarized temporal characteristics will be used to determine whether different types of trajectories emerge. Hierarchical cluster analysis will label patients for each of the cluster solutions and the usefulness of patient labelling will be evaluated by their predicted gait performance. The extracted patient type will be included in random forests or boosting to evaluate its importance. The extracted patient type could also be used jointly with other predictors suggested as important in either a linear/logistic (mixed) model or an extended cox proportional hazard model, which are more traditional statistical approaches. While predictive performance remains the key goal, such models would be more interpretable on the potential underlying mechanism, with parameter estimates and confidence intervals.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1
Non-ambulatory acute stroke survivors at admission (Functional Ambulation Categories (FAC) ≤ 2)
Follow-up assessments
Longitudinal evaluation of recovery
Cohort 2
Ambulatory acute stroke survivors at admission (Functional Ambulation Categories (FAC) ≥ 3)
Follow-up assessments
Longitudinal evaluation of recovery
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Follow-up assessments
Longitudinal evaluation of recovery
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Hospitalized at the Neurology ward of UZ Brussel
* Diagnosed with first-ever stroke (as defined by the World Health Organisation)
* Able to provide written or verbal informed consent
Exclusion Criteria
* Severe deficits of communication, memory or understanding
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universitair Ziekenhuis Brussel
OTHER
Vrije Universiteit Brussel
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lotte Cuypers
Doctoral Researcher
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David Beckwée, Prof. Ph.D
Role: STUDY_CHAIR
Vrije Universiteit Brussel
Eva Swinnen, Prof. Ph.D
Role: STUDY_CHAIR
Vrije Universiteit Brussel
Lotte Cuypers, Dra.
Role: PRINCIPAL_INVESTIGATOR
Vrije Universiteit Brussel
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Universitair Ziekenhuis Brussel
Jette, Brussels Capital, Belgium
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Muscle trajectories
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.